Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease

References

• McDowell C, Farooq U, Haseeb M. Inflammatory bowel disease. Treasure Island (FL): StatPearls Publishing;2024.
   Google Scholar
• Jain M, Venkataraman J. Inflammatory bowel disease: an Indian perspective. Indian J Med Res. 2021;153(4):421–430. doi: 10.4103/ijmr.IJMR_936_18.
   PubMed Web of Science ®Google Scholar
• Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27(8):1266–1280. doi: 10.1111/j.1440-1746.2012.07150.x.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Boucher G, Waterman M, et al. Genetic predictors of benign course of ulcerative colitis-A North American inflammatory bowel disease genetics consortium study. Inflamm Bowel Dis. 2016;22(10):2311–2316. doi: 10.1097/MIB.0000000000000913.
   PubMed Web of Science ®Google Scholar
• Lepage P, Häsler R, Spehlmann ME, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141(1):227–236. doi: 10.1053/j.gastro.2011.04.011.
   PubMed Web of Science ®Google Scholar
• Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2687–2692. doi: 10.1038/ajg.2010.398.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–217. doi: 10.1038/nrgastro.2015.34.
   PubMed Web of Science ®Google Scholar
• Gowd V, Jori C, Chaudhary AA, et al. Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease. J Nutr Biochem. 2022;109:109101. doi: 10.1016/j.jnutbio.2022.109101.
   PubMed Web of Science ®Google Scholar
• Selewski DT, Shah GV, Segal BM, et al. Natalizumab (Tysabri). AJNR Am J Neuroradiol. 2010;31(9):1588–1590. doi: 10.3174/ajnr.A2226.
   PubMed Web of Science ®Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–1058.e3. doi: 10.1053/j.gastro.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med (Lausanne). 2021;8:765474. doi: 10.3389/fmed.2021.765474.
   PubMed Web of Science ®Google Scholar
• Mikami Y, Tsunoda J, Suzuki S, et al. Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis. Digestion. 2023;104(1):58–65. doi: 10.1159/000527452.
   PubMed Web of Science ®Google Scholar
• Laredo V, García-Mateo S, Martínez-Domínguez SJ, et al. Risk of cancer in patients with inflammatory bowel diseases and keys for patient management. Cancers (Basel). 2023;15(3):871. doi: 10.3390/cancers15030871.
   PubMed Web of Science ®Google Scholar
• Bruscoli S, Febo M, Riccardi C, et al. Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice. Front Immunol. 2021;12:691480. doi: 10.3389/fimmu.2021.691480.
   PubMed Web of Science ®Google Scholar
• Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301–307. doi: 10.1016/j.jbspin.2018.07.004.
   PubMed Web of Science ®Google Scholar
• Pannu AK. Methotrexate overdose in clinical practice. Curr Drug Metab. 2019;20(9):714–719. doi: 10.2174/1389200220666190806140844.
   PubMed Web of Science ®Google Scholar
• de Boer NKH, Peyrin-Biroulet L, Jharap B, et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis. 2018;12(5):610–620. doi: 10.1093/ecco-jcc/jjx181.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91(6):660–668. doi: 10.1136/jnnp-2019-322326.
   PubMed Web of Science ®Google Scholar
• Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016;10(8):989–997. doi: 10.1093/ecco-jcc/jjw053.
   PubMed Web of Science ®Google Scholar
• Gosselt H, Van Lint J, Kosse L, et al. POS1532-HPR Sex differences in the experienced burden of adverse drug reactions attributed to adalimumab and etanercept by patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2022;81(1):1111.1–1111. doi: 10.1136/annrheumdis-2022-eular.2787.
   Google Scholar
• Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int. 2013;2013:581631. doi: 10.1155/2013/581631.
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Positioning Ustekinumab in Crohn’s disease: from clinical evidence to clinical practice. J Crohns Colitis. 2017;11(10):1258–1266. doi: 10.1093/ecco-jcc/jjx079.
   PubMed Web of Science ®Google Scholar
• Momen Majumder MS, Haq SA, Rasker JJ. Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. J Med Case Rep. 2023;17(1):71. doi: 10.1186/s13256-023-03796-2.
   PubMedGoogle Scholar
• Moodley D, Yoshida H, Mostafavi S, et al. Network pharmacology of JAK inhibitors. Proc Natl Acad Sci USA. 2016;113(35):9852–9857. doi: 10.1073/pnas.1610253113.
   PubMed Web of Science ®Google Scholar
• Cordes F, Foell D, Ding JN, et al. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn’s disease. World J Gastroenterol. 2020;26(28):4055–4075. doi: 10.3748/wjg.v26.i28.4055.
   PubMed Web of Science ®Google Scholar
• Houslay MD, Schafer P, Zhang KYJ. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503–1519. doi: 10.1016/S1359-6446(05)03622-6.
   PubMed Web of Science ®Google Scholar
• Schett G, Sloan VS, Stevens RM, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2(5):271–278. doi: 10.1177/1759720X10381432.
   PubMedGoogle Scholar
• Zhang D. Toll-like receptors and inflammatory bowel disease. Front Immunol. 2018;9:1–9.
   Google Scholar
• Guo Q, Jin Y, Chen X, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9(1):53. doi: 10.1038/s41392-024-01757-9.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296(6):G1167–79. doi: 10.1152/ajpgi.90496.2008.
   PubMed Web of Science ®Google Scholar
• Tian CM, Zhang Y, Yang MF, et al. Stem cell therapy in inflammatory bowel disease: a review of achievements and challenges. J Inflamm Res. 2023;16:2089–2119. doi: 10.2147/JIR.S400447.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su Q, Zhang B, et al. Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther. 2021;12(1):32. doi: 10.1186/s13287-020-02095-7.
   PubMed Web of Science ®Google Scholar
• Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: current perspectives. World J Gastroenterol. 2023;29(35):5178–5179. doi: 10.3748/wjg.v29.i14.2078.
   PubMed Web of Science ®Google Scholar
• Saez A, Gomez‐bris R, Herrero‐fernandez B, et al. Innate lymphoid cells in intestinal homeostasis and inflammatory bowel disease. Int J Mol Sci. 2021;22(14):7618. doi: 10.3390/ijms22147618.
   PubMed Web of Science ®Google Scholar
• Amamou A, Rouland M, Yaker L, et al. Dietary salt exacerbates intestinal fibrosis in chronic TNBS colitis via fibroblasts activation. Sci Rep. 2021;11(1):15055. doi: 10.1038/s41598-021-94280-8.
   PubMed Web of Science ®Google Scholar
• Alfredsson J, Wick MJ. Mechanism of fibrosis and stricture formation in Crohn’s disease. Scand J Immunol. 2020;92(6):e12990. doi: 10.1111/sji.12990.
   PubMed Web of Science ®Google Scholar
• Ashique S, Mishra N, Garg A, et al. Recent updates on correlation between reactive oxygen species and synbiotics for effective management of ulcerative colitis. Front Nutr. 2023;10:1126579. doi: 10.3389/fnut.2023.1126579.
   Google Scholar
• Roberti A, Chaffey LE, Greaves DR. NF-κB signaling and inflammation-drug repurposing to treat inflammatory disorders? Biology (Basel). 2022;11(3):372. doi: 10.3390/biology11030372.
   PubMedGoogle Scholar
• Shao BZ, Yao Y, Zhai JS, et al. The role of autophagy in inflammatory bowel disease. Front Physiol. 2021;12:621132. doi: 10.3389/fphys.2021.621132.
   PubMed Web of Science ®Google Scholar
• Danese S, Peyrin-Biroulet L. Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise. Inflamm Bowel Dis. 2021;27(12):2023–2030. doi: 10.1093/ibd/izab135.
   PubMed Web of Science ®Google Scholar
• Cui X, Teng Y, Hu Y, et al. Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease. Int Immunopharmacol. 2024;126:111238. doi: 10.1016/j.intimp.2023.111238.
   PubMed Web of Science ®Google Scholar
• Danese S, Neurath MF, Kopoń A, et al. Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(11):2526–2534.e9. doi: 10.1016/j.cgh.2019.12.032.
   PubMed Web of Science ®Google Scholar
• Pan W, Xiang L, Liang X, et al. Vitronectin destroyed intestinal epithelial cell differentiation through activation of PDE4-mediated ferroptosis in inflammatory bowel disease. Med Inflamm. 2023;2023:6623329–6623316. doi: 10.1155/2023/6623329.
   PubMed Web of Science ®Google Scholar
• Marafini I, Troncone E, Salvatori S, et al. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases. Pharmacol Res. 2020;155:104757. doi: 10.1016/j.phrs.2020.104757.
   PubMed Web of Science ®Google Scholar
• Hassan HA, Samy W, Mohammed HO, et al. Ameliorative effects of androstenediol against acetic acid-induced colitis in male Wistar rats via inhibiting TLR4-mediated PI3K/Akt and NF-κB pathways through estrogen receptor β activation. Int Immunopharmacol. 2024;127:111414. doi: 10.1016/j.intimp.2023.111414.
   PubMed Web of Science ®Google Scholar
• Jeon YD, Kim SJ. Ameliorative effect of Pu-erh tea on DSS-induced colitis through regulation of NF-κB activation in mice. Biomed Sci Letters. 2021;27(4):248–254. doi: 10.15616/BSL.2021.27.4.248.
   Google Scholar
• Atreya R, Peyrin-Biroulet L, Klymenko A, et al. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol. 2020;5(12):1063–1075. doi: 10.1016/S2468-1253(20)30301-0.
   PubMed Web of Science ®Google Scholar
• Liang J, Zhang H, Wang D, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut. 2011;61(3):468–469. doi: 10.1136/gutjnl-2011-300083.
   PubMed Web of Science ®Google Scholar
• Liu L, Chiu PWY, Lam PK, et al. Effect of local injection of mesenchymal stem cells on healing of sutured gastric perforation in an experimental model. Br J Surg. 2015;102(2):e158–68. Jan doi: 10.1002/bjs.9724.
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn’s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65(5):713–720. doi: 10.1097/DCR.0000000000002325.
   PubMed Web of Science ®Google Scholar
• Malasevskaia I, Al-Awadhi AA, Raza FA. Adipose-derived stem cells-A promising method of therapy for perianal fistula: a traditional review. J Middle East North Africa Sci. 2021;7:8–17.
   Google Scholar
• Zhou J, Li M, Chen Q, et al. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nat Commun. 2022;13(1):3432. doi: 10.1038/s41467-022-31171-0.
   Google Scholar
• Huang C, Hao W, Wang X, et al. Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022. Front Microbiol. 2023;14:1211271. doi: 10.3389/fmicb.2023.1211271.
   Google Scholar
• Schreiber S, Aden K, Bernardes JP, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354–2366.e11. doi: 10.1053/j.gastro.2021.02.062.
   PubMed Web of Science ®Google Scholar
• Roy S, Dhaneshwar S, Mahmood T. Exploring the potential of IL-1β inhibitor diacerein and its combination with 5-aminosalicylic acid for the possible ameliorating effect in TNB sinduced experimental colitis in Wistar rats. CDTH. 2022;17(2):132–146. doi: 10.2174/1574885517666220328142715.
   Google Scholar
• Almezgagi M, Ms T, Yu Z, et al. Evaluation of diacerein efficacy on colitis as anti-inflammatory and anti-oxidant and its role in enhancing of colon barrier in mice. Acta Pol Pharm. 2023;80(4):649–659.
   Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650–1664.e8. doi: 10.1053/j.gastro.2022.01.047.
   PubMed Web of Science ®Google Scholar
• Choi D, Sheridan H, Bhat S. Risankizumab-rzaa: a new therapeutic option for the treatment of Crohn’s disease. Ann Pharmacother. 2022;57(5):579–584. doi: 10.1177/10600280221130450.
   PubMed Web of Science ®Google Scholar
• Li X, Fang S, Yu Y, et al. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. Chem Eng J. 2022;445:136438. doi: 10.1016/j.cej.2022.136438.
   Web of Science ®Google Scholar
• Sandborn WJ, Vermeire S, Tyrrell H, et al. Etrolizumab for the treatment of ulcerative colitis and Crohn’s disease: an overview of the phase 3 clinical program. Adv Ther. 2020;37(7):3417–3431. doi: 10.1007/s12325-020-01366-2.
   PubMed Web of Science ®Google Scholar
• Palma E, Costa N, Molinaro R, et al. Improvement of the therapeutic treatment of inflammatory bowel diseases following rectal administration of mesalazine-loaded chitosan microparticles vs Asamax ®. Carbohydr Polym. 2019;212:430–438. doi: 10.1016/j.carbpol.2019.02.049.
   PubMed Web of Science ®Google Scholar
• Oshi MA, Naeem M, Bae J, et al. Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydr Polym. 2018;198:434–442. doi: 10.1016/j.carbpol.2018.06.107.
   PubMed Web of Science ®Google Scholar
• Tie S, Su W, Chen Y, et al. Dual targeting procyanidin nanoparticles with glutathione response for colitis treatment. Chem Eng J. 2022;441:136095. doi: 10.1016/j.cej.2022.136095.
   Web of Science ®Google Scholar
• Shrestha N, Xu Y, Prévost JRC, et al. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Acta Biomater. 2022;140:561–572. doi: 10.1016/j.actbio.2021.12.015.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang Y, Zhang J, et al. Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. Acta Pharm Sin B. 2020;10(10):1966–1976. doi: 10.1016/j.apsb.2020.07.019.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang Y, Fu Y, et al. Modulating AHR function offers exciting therapeutic potential in gut immunity and inflammation. Cell Biosci. 2023;13(1):85. doi: 10.1186/s13578-023-01046-y.
   PubMed Web of Science ®Google Scholar
• Cicio A, Serio R, Zizzo MG. Anti-inflammatory potential of brassicaceae-derived phytochemicals: in vitro and in vivo evidence for a putative role in the prevention and treatment of IBD. Nutrients. 2023;15(1):31. doi: 10.3390/nu15010031.
   Web of Science ®Google Scholar
• Tundis R, Xiao J, Silva AS, et al. Health-promoting properties and potential application in the food industry of Citrus medica L. and Citrus × clementina Hort. Ex Tan. essential oils and their main constituents. Plants. 2023;12(5):991. doi: 10.3390/plants12050991.
   Google Scholar
• Abuzaid H, Amin E, Moawad A, et al. Liquid chromatography high-resolution mass spectrometry analysis, phytochemical and biological study of two Aizoaceae plants plants: a new kaempferol derivative from Trianthema portulacastrum L. Pharmacognosy Res. 2020;10:24–30.
   Google Scholar
• Rehman R, Pinkos B, Shapiro JM, et al. Nutritional management of inflammatory bowel disease. R I Med J (2013). 2022;105(10):31–37.
   PubMedGoogle Scholar
• Reznikov EA, Suskind DL. Current nutritional therapies in inflammatory bowel disease: improving clinical remission rates and sustainability of long-term dietary therapies. Nutrients. 2023;15(3):668. doi: 10.3390/nu15030668.
   Google Scholar
• Liu H, Johnston LJ, Wang F, et al. Triggers for the Nrf2/ARE signaling pathway and its nutritional regulation: potential therapeutic applications of ulcerative colitis. Int J Mol Sci. 2021;2:1–13.
   Google Scholar
• Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L, et al. Nutrition and supplementation in ulcerative colitis. Nutrients. 2022;14(12):2469. doi: 10.3390/nu14122469.
   Google Scholar
• Jurjus A, El Masri J, Ghazi M, et al. Mechanism of action of melatonin as a potential adjuvant therapy in inflammatory bowel disease and colorectal cancer. Nutrients. 2024;16(8):1236. doi: 10.3390/nu16081236.
   PubMed Web of Science ®Google Scholar
• Casili G, Cordaro M, Impellizzeri D, et al. Dimethyl fumarate reduces inflammatory responses in experimental colitis. J Crohns Colitis. 2016;10(4):472–483. doi: 10.1093/ecco-jcc/jjv231.
   PubMed Web of Science ®Google Scholar
• Pituch-Zdanowska A, Dembiński Ł, Banaszkiewicz A. Old but fancy: curcumin in ulcerative colitis-current overview. Nutrients. 2022;14(24):5249. doi: 10.3390/nu14245249.
   PubMed Web of Science ®Google Scholar